ArticleJAMA ophthalmology2019
Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma.
Article in JAMA ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Multimodal imaging for diagnosis and follow-up of primary vitreoretinal lymphoma: A systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Diagnostic Value of Clinical and Optical Coherence Tomography Findings in Primary Vitreoretinal Lymphoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Utility of liquid-based cytology and cell block obtained by vitrectomy under infusion to diagnose vitreoretinal lymphoma.Japanese journal of ophthalmology · 2026Article
- Spectrally Resolved (Colour-Coded) Fundus Autofluorescence Using the EIDON System in Vitreoretinal Lymphoma.Ophthalmology and therapy · 2026Article
- Ocular Imaging in Intraocular Lymphoma: A Review.Clinical & experimental ophthalmology · 2026Review
- Sequential multimodal imaging of varicella-zoster virus-associated acute retinal necrosis: Insights supporting a neurotropic hypothesis.European journal of ophthalmology · 2026Article
- Optical coherence tomography features and visual prognosis in vitreoretinal lymphoma: a structured phenotyping study.Frontiers in medicine · 2026Article
- Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood science (Baltimore, Md.) · 2025Review
- Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).Eye and vision (London, England) · 2025Review
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma.European journal of ophthalmology · 2024Review
- Optical coherence tomography features in vitreoretinal lymphoma compared with non-infectious uveitis.BMC ophthalmology · 2024Article
- Multimodal imaging in a case of presumed secondary vitreoretinal lymphoma presenting with inner retina and optic nerve head infiltration.American journal of ophthalmology case reports · 2024Article
- Case report: Intraretinal hyperflow microinfiltration lesions on swept-source optical coherence tomography angiography as a potential biomarker of primary vitreoretinal lymphoma.Frontiers in medicine · 2024Article
- Electroretinographic and Optical Coherence Tomographic Evaluations of Eyes with Vitreoretinal Lymphoma.Journal of clinical medicine · 2023Article
- Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.BMC ophthalmology · 2022Article
- Multimodal diagnostic imaging in primary vitreoretinal lymphoma.International journal of retina and vitreous · 2022Review
- Article
- Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma.American journal of ophthalmology · 2022Article
- Secondary vitreoretinal lymphoma with spontaneous regression.American journal of ophthalmology case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Vitreoretinal lymphoma is a diagnostic challenge and the pathophysiology is still unclear. Objective: To describe an imaging finding seen on optical coherence tomography (OCT) of patients with vitreoretinal lymphoma. Design, Setting, and Participants: This case series study was a retrospective medical record review of patients who received a diagnosis of vitreoretinal lymphoma at the Department of Ophthalmology at Northwestern University between July 2014 and January 2016. Main Outcomes and Measures: Optical coherence tomography findings in vitreoretinal lymphoma. Results: We identified 7 patients (4 women [57.1%]; mean [range] age, 62.4 [45-75] years; 12 eyes) with intraocular lymphoma involving the retina (5 patients [71.4%] with primary vitreoretinal or central nervous system lymphoma with ocular involvement, 1 patient [14.3%] with testicular lymphoma with secondary central nervous system lymphoma and vitreoretinal lymphoma, and 1 patient [14.3%] with secondary vitreoretinal lymphoma). We identified vertical hyperreflective lesions that showed moderate or high reflectivity and affected all layers of the neuroretina in 5 patients (7 of 12 eyes [58.3%]). These often preceded the development of subretinal pigment epithelial deposits and were often localized around second-order and third-order retinal vessels. In most cases, they resolved with minimal or no scarring after the initiation of chemotherapy. Conclusions and Relevance: Vertical hyperreflective lesions are a common physical finding on OCT in eyes with vitreoretinal lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.